This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

BioCryst Competition for IV Flu Drug: BioBuzz

WASHINGTON, D.C. ( TheStreet) -- The U.S. government bolstered its flu defenses Thursday night with orders for intravenous versions of Roche's Tamiflu and GlaxoSmithKline's (GSK - Get Report) Relenza.

The new orders -- 10,000 courses of each drug with an option to purchase more -- will be added to the national flu drug stockpile set up to treat seriously ill and hospitalized H1N1 flu patients.

Earlier Thursday, BioCryst Pharmaceuticals (BCRX - Get Report) said it shipped 10,000 courses of its intravenous flu drug peramivir to the U.S government, also with an option to acquire more. The announcement sent shares of the company sharply higher.

But the government's decision to purchase intravenous versions of Tamiflu and Relenza -- both of which are less expensive than peramivir -- could be seen by investors Friday as a setback to BioCryst.

Until Thursday night, it was widely believed that BioCryst's peramivir would be the only intravenous flu drug available.

Tamiflu, Relenza and peramivir are antiviral drugs that all act against the flu virus in similar ways. Tamiflu (as a pill) and Relenza (as an inhaled mist) are already approved by the U.S. Food and Drug Administration and widely used. Peramivir has not undergone pivotal studies yet and is not FDA approved. Regulators have made the drug available to doctors during the H1N1 flu pandemic under an emergency use authorization.

The U.S. Department of Health and Human Services ordered 10,000 courses each of intravenous Tamiflu, Relenza and peramivir, with an option to order another 30,000 courses of each.

The government is paying an average of $450 per course for intravenous Tamiflu and Relenza, according to a story in the New York Times. Thursday, the government said it would purchase peramivir at a price of $2,250 per course of treatment.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
BCRX $10.20 0.00%
GSK $47.42 0.00%
AAPL $128.46 0.00%
FB $78.97 0.00%
GOOG $558.40 0.00%


DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs